NCT05875961View on ClinicalTrials.gov

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

June 15, 2023

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2024

Conditions
Influenza, HumanInfectionsRespiratory Tract InfectionsVirus DiseasesInfection Viral
Interventions
BIOLOGICAL

Low dose A/H2N3c + standard dose MF59

Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

BIOLOGICAL

Intermediate dose A/H2N3c + standard dose MF59

Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

BIOLOGICAL

High dose A/H2N3c + standard dose MF59

Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

BIOLOGICAL

High dose A/H2N3c non-adjuvanted

Two intramuscular injections (3 weeks apart) of cell culture-derived non-adjuvanted H2N3 vaccine

BIOLOGICAL

Lowest dose A/H2N3c + high dose MF59

Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

BIOLOGICAL

Low dose A/H2N3c + high dose MF59

Two intramuscular injections (3 weeks apart) of cell culture-derived MF59 adjuvanted H2N3 vaccine

Trial Locations (7)

20854

Meridian Clinical Research, Rockville

58134

Meridian Clinical Research, Omaha

68510

Meridian Clinical Research, Lincoln

Unknown

West Visayas State University Medical Center, Iloilo City

Manila Doctors Hospital, Manila

Quirino Memorial Medical Center, Quezon City

Silang Specialists Medical Center, Silang

All Listed Sponsors
collaborator

Biomedical Advanced Research and Development Authority

FED

lead

Seqirus

INDUSTRY